Prognoses of patients with melanoma who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: a multicentre retrospective study

被引：1
|
作者：
Kato, Junji [1 ]
Namikawa, Kenjiro [2 ]
Uehara, Jiro [3 ]
Nomura, Motoo [4 ]
Nakamura, Yasuhiro [5 ]
Uhara, Hisashi [1 ]
Uchi, Hiroshi [6 ]
Yoshikawa, Shusuke [7 ]
Kiniwa, Yukiko [8 ]
Nakamura, Yoshiyuki [9 ]
Miyagawa, Takuya [10 ]
Matsushita, Shigeto [11 ]
Takenouchi, Tatsuya [12 ]
Hatta, Naohito [13 ]
Ohno, Fumitaka [14 ]
Maeda, Taku [15 ,16 ]
Fukushima, Satoshi [17 ]
Yamazaki, Naoya
机构：
[1] Sapporo Med Univ, Dept Dermatol, Sapporo, Hokkaido, Japan
[2] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan
[3] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Dermatol Oncol, Tokyo, Japan
[4] Kyoto Univ, Dept Clin Oncol, Kyoto, Japan
[5] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, Saitama, Japan
[6] Natl Hosp Org Kyushu Canc Ctr, Dept Dermatooncol, Fukuoka, Japan
[7] Shizuoka Canc Ctr, Div Dermatol, Shizuoka, Japan
[8] Shinshu Univ, Dept Dermatol, Nagano, Japan
[9] Univ Tsukuba, Dept Dermatol, Tsukuba, Ibaraki, Japan
[10] Univ Tokyo, Dept Dermatol, Grad Sch Med, Tokyo, Japan
[11] Natl Hosp Org Kagoshima Med Ctr, Dept Dermatooncol Dermatol, Kagoshima, Japan
[12] Niigata Canc Ctr, Dept Dermatol, Niigata, Japan
[13] Toyama Prefectural Cent Hosp, Dept Dermatol, Toyama, Japan
[14] Kyushu Univ, Dept Dermatol, Fukuoka, Japan
[15] Hokkaido Univ, Dept Plast & Reconstruct Surg, Fac Med, Sapporo, Hokkaido, Japan
[16] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan
[17] Kumamoto Univ, Dept Dermatol & Plast Surg, Kumamoto, Japan
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 187卷 / 04期
关键词：
DISCONTINUATION;
D O I：
10.1111/bjd.21276
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：594 / 596
页数：3
相关论文
共 50 条
  • [21] Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis
    Momotow, Jesko
    Buehnen, Ina
    Trautmann-Grill, Karolin
    Kobbe, Guido
    Hahn, Dennis
    Schroers, Roland
    Heinrich, Bernhard
    Gaska, Tobias
    Forstbauer, Helmut
    Schmidt, Burkhard
    Boger, Regina
    Huettmann, Andreas
    Heil, Gerhard
    Kraemer, Doris M.
    Krueger, William
    Zeremski, Vanja
    Grobe, Norbert
    Jentsch-Ullrich, Kathleen
    Griesinger, Frank
    Fuchs, Michael
    von Tresckow, Bastian
    Borchmann, Peter
    Engert, Andreas
    Broeckelmann, Paul J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : 401 - 404
  • [22] Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients
    Valentine Heidelberger
    François Goldwasser
    Nora Kramkimel
    Anne Jouinot
    Nathalie Franck
    Jennifer Arrondeau
    Sarah Guégan
    Audrey Mansuet-Lupo
    Jérôme Alexandre
    Diane Damotte
    Marie-Françoise Avril
    Nicolas Dupin
    Sélim Aractingi
    Investigational New Drugs, 2017, 35 : 842 - 847
  • [23] Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients
    Heidelberger, Valentine
    Goldwasser, Francois
    Kramkimel, Nora
    Jouinot, Anne
    Franck, Nathalie
    Arrondeau, Jennifer
    Guegan, Sarah
    Mansuet-Lupo, Audrey
    Alexandre, Jerome
    Damotte, Diane
    Avril, Marie-Francoise
    Dupin, Nicolas
    Aractingi, Selim
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 842 - 847
  • [24] Unexpected response with palliative conventional therapy in head and neck squamous cell carcinoma after anti-programmed death-1 progression
    Denaro, Nerina
    Merlano, Marco Carlo
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (03): : E42 - E47
  • [25] Comparison of Efficacy and Safety of Anti-Programmed Cell Death-1 Antibody Plus Lenvatinib and Chemotherapy as First-Line Therapy for Patients with Stage IV Gallbladder Cancer: A Real-World Study in a Chinese Population
    Wu, Tiantian
    Pu, Changsheng
    Wang, Qiang
    Zhang, Keming
    BIOMEDICINES, 2023, 11 (11)
  • [26] Anti-programmed death ligand 1 immunotherapy in patients with limited-stage small cell lung cancer: a real-world exploratory study
    Yao, Nan
    Qin, Zhaohui
    Ma, Ji
    Lu, Jiaying
    Sun, Kaiguo
    Zhang, Yiqing
    Qu, Wanxi
    Cui, Li
    Yuan, Shiwang
    Jiang, Aijun
    Li, Na
    Tong, Shaodong
    Yao, Yuanhu
    JOURNAL OF CHEMOTHERAPY, 2023, 35 (05) : 448 - 454
  • [27] Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: A cross-sectional study
    Dousset, Lea
    Pacaud, Alize
    Barnetche, Thomas
    Kostine, Marie
    Dutriaux, Caroline
    Pham-Ledard, Anne
    Beylot-Barry, Marie
    Gerard, Emilie
    Prey, Sorilla
    Andreu, Nicolas
    Boniface, Katia
    Seneschal, Julien
    JAAD INTERNATIONAL, 2021, 5 : 112 - 120
  • [28] Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
    Ascierto, Paolo Antonio
    Lipson, Evan J.
    Dummer, Reinhard
    Larkin, James
    Long, Georgina V.
    Sanborn, Rachel E.
    Chiarion-Sileni, Vanna
    Dreno, Brigitte
    Dalle, Stephane
    Schadendorf, Dirk
    Callahan, Margaret K.
    Nyakas, Marta
    Atkinson, Victoria
    Gomez-Roca, Carlos Alberto
    Yamazaki, Naoya
    Tawbi, Hussein A.
    Sarkis, Naomey
    Warad, Deepti
    Dolfi, Sonia
    Mitra, Priyam
    Suryawanshi, Satyendra
    Grob, Jean-Jacques
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2724 - +
  • [29] Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis
    Bair, Steven M.
    Strelec, Lauren E.
    Feldman, Tatyana A.
    Ahmed, Gulrayz
    Armand, Philippe
    Shah, Nirav N.
    Singavi, Arun N.
    Reddy, Nishitha
    Khan, Nadia
    Andreadis, Charalambos
    Khoan Vu
    Huntington, Scott F.
    Giri, Smith
    Ujjanii, Chaitra
    Howlett, Christina
    Faheem, Malik
    Youngman, Matthew R.
    Nasta, Sunita D.
    Landsburg, Daniel J.
    Schuster, Stephen J.
    Svoboda, Jakub
    ONCOLOGIST, 2019, 24 (07): : 955 - 962
  • [30] SURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS OF NIVOLUMAB (NIVO, ANTI-PROGRAMMED DEATH-1) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCED MELANOMA (MEL)
    Sznol, Mario
    Kluger, Harriet
    Callahan, Margaret K.
    Postow, Michael A.
    Gordon, RuthAnn
    Seal, Neil H.
    Rizvi, Naiyer A.
    Lesokhin, Alexander M.
    Atkins, Michael B.
    Kirkwood, John M.
    Burke, Matthew M.
    Ralabate, Amanda
    Rivera, Angel
    Kronenberg, Stephanie A.
    Agunwamba, Blessing U.
    Feely, William
    Quan, Hong
    Krishnan, Suba
    Gupta, Ashok
    Wolchok, Jedd D.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 188 - 188
12345